Some trouble with Chantix
The Carlat Psychiatry Report, Volume 6, Number 1, January 2008
https://www.thecarlatreport.com/newsletter-issue/tcprv6n1/
Issue Links: Learning Objectives | Editorial Information
Topics: Smoking Cessation Agents
John O’Reardon, MD
On November 20, 2007, the FDA issued an “early communication” warning about possible dangerous side effects of Chantix (varenicline), a new smoking cessation agent that affects brain nicotine receptors. Several cases of new-onset depression, suicidal ideation, and aggressive or erratic behavior have been reported via the Medwatch program.
You can't view details of this content, please login or buy subscription here
John O’Reardon, MD
Associate Professor of Psychiatry University of Pennsylvania Health System
Dr. O’Reardon has disclosed that he has received research grants from Neuronetics, Cyberonics, Cerex Biopharma, and Pfizer, and is on the speaker's bureaus of Eli Lilly and Bristol-Myers Squibb. Dr. Carlat has found that there is no evidence of commercial bias in this educational activity.